This contract expires in 221 days (Jan 18, 2027).
EXELAN PHARMACEUTICALS INC - LENALIDOMIDE - ONCOLOGY TREATMENT FOR VETERANS DIFFERENT MILLIGRAMS.
Key Details
Description
LENALIDOMIDE - ONCOLOGY TREATMENT FOR VETERANS DIFFERENT MILLIGRAMS.
Context & Analysis
On Jan 14, 2026, Department of Veterans Affairs obligated $545,433.7 to EXELAN PHARMACEUTICALS INC for lenalidomide - oncology treatment for veterans different milligrams.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in CARY, NC. The contract is scheduled through Jan 18, 2027 — approximately 7 months remaining. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.